None listed
Conditions
Brief summary
To assess the clinical utility of using a non-invasive haemodynamic monitoring device (the Clearsight TM system) in the cardiac assessment of patients undergoing CRRT and IHD To evaluate the feasibility of using the Clearsight TM system on patients that are currently on CRRT To evaluate the feasibility of using the Clearsight TM system on patients that are currently on IHD To evaluate the haemodynamic changes that occur during a CRRT session and how are these changes correlated to the clinical status of the patient To evaluate the haemodynamic changes that occur during an IHD session and how are these changes correlated to the clinical status of the patient Patients rercruited would have already been receiving IHD or CRRT and were then approached to enter this study. Patients would not have their IHD or CRRT intervention altered in anyway. The ClearSight cardiac output monitoring device is a small pressure cuff that is applied the the middle phalanx of either the 2nd, 3rd or 4th finger. This allows for continuous monitoring of cardiac output
Interventions
Participants: participants will undergo intermittent haemodialysis (IHD) or continuous renal replacement therapy (CRRT) as per usual prescribed by nephrologist or intensivist. The additional requirement that participants undergo as part of the study is to allow for an inflatable cuff to be placed over the middle phalanx of either hand of the 2nd, 3rd or 4th finger. They will be also asked of their experiences with the device being applied during time on haemodialysis. The on patient will only un
Participants: participants will undergo intermittent haemodialysis (IHD) or continuous renal replacement therapy (CRRT) as per usual prescribed by nephrologist or intensivist. The additional requirement that participants undergo as part of the study is to allow for an inflatable cuff to be placed over the middle phalanx of either hand of the 2nd, 3rd or 4th finger. They will be also asked of their experiences with the device being applied during time on haemodialysis. The on patient will only undergo monitoring during a single dialysis session. Monitoring: use of the device and monitoring is continuous. Patients will be monitored with device on up to 30 minutes before and after their IHD or CRRT
Sponsors
Austin Health
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients will be included if the following criteria are fulfilled: o They are adult (patients are 18 years old or older ) o The patient is currently undergoing either CRRT or IHD o Informed consent can be provided by the patient or medical treatment decision maker o At least one arm without arteriovenous fistula and/or graft
Exclusion criteria
Consistent with the recommendations using the ClearSight system, Patients will only be excluded if they have a clinical history of severe peripheral vascular disease or Raynaud’s disease, intubated or unable to objectively report symptoms.
Outcome results
None listed